Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer

BACKGROUND: We previously reported that survivin-2B, a splicing variant of survivin, was expressed in various types of tumors and that survivin-2B peptide might serve as a potent immunogenic cancer vaccine. The objective of this study was to examine the toxicity of and to clinically and immunologica...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsuruma, Tetsuhiro, Iwayama, Yuji, Ohmura, Tosei, Katsuramaki, Tadashi, Hata, Fumitake, Furuhata, Tomohisa, Yamaguchi, Koji, Kimura, Yasutoshi, Torigoe, Toshihiko, Toyota, Nobuhiko, Yagihashi, Atsuhito, Hirohashi, Yoshihiko, Asanuma, Hiroko, Shimozawa, Kumiko, Okazaki, Minoru, Mizushima, Yasuhiro, Nomura, Naohiro, Sato, Noriyuki, Hirata, Koichi
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2430193/
https://www.ncbi.nlm.nih.gov/pubmed/18471305
http://dx.doi.org/10.1186/1479-5876-6-24

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2430193/
https://www.ncbi.nlm.nih.gov/pubmed/18471305
http://dx.doi.org/10.1186/1479-5876-6-24

Ejemplares similares